COMMUNIQUÉS West-GlobeNewswire

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
07/11/2025
Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors MIRAMAR, Fla., Nov. 07 [...]
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
07/11/2025
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis ( [...]
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
07/11/2025
GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related discontinuations Dose dependent [...]
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
07/11/2025
Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-year Record quarterly adjusted non-GAAP EBITDA [...]
Nonprofit Human Appeal Launches Winter Coat Drive Across US East Coast
07/11/2025
Human Appeal’s first U.S. domestic campaign aims to collect 3,500 coats for families in need FAIRFAX, Va., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Global humanitarian aid nonprofit Human Appeal has officially launched its [...]
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
07/11/2025
Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to [...]
Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance
07/11/2025
Reports third quarter 2025 total revenue of $7.8 million , representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, [...]
Sanuwave Announces Q3 FY2025 Financial Results
07/11/2025
Q3 2025 revenues were $11.5 million , up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9% , versus 75.5% in Q3 2024. GAAP Operating [...]
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
07/11/2025
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on the [...]
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
07/11/2025
Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical [...]
Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
07/11/2025
– Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups – – In addition to robust liver-centric effects, HU6 resulted in fat-selective weight loss with [...]
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
07/11/2025
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be [...]
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...
07/11/2025
ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la [...]
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
07/11/2025
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies Dr. Adrian Bot, a renowned biopharmaceutical founder and scientist, has joined [...]
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
07/11/2025
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant [...]
Vaxart to Host Upcoming Conference Calls
07/11/2025
Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- [...]
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
07/11/2025
The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS (Vafidemstat) Received feedback from the FDA [...]
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
07/11/2025
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash [...]
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
07/11/2025
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years and older compared [...]

Pages